PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has announced plans to invest over $365 million in new and expanded facilities to support the packaging of drug-device combination products. The expansion focuses on advanced drug delivery systems,
TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to introduce CleanScribe™ RNA Polymerase. This novel enzyme reduces the formation of double-stranded RNA (dsRNA) by up to 85% during in vitro transcription (IVT) for mRNA production, a key
Lonza has entered into a long-term commercial supply agreement with Vertex for the production of CASGEVY (exagamglogene autotemcel), the first cell therapy based on CRISPR/Cas9 technology. The therapy is designed as a one-time treatment for patients with transfusion-dependent beta-thalassemia or
Quell Therapeutics Ltd and eXmoor pharma have announced a strategic partnership to manufacture Quell’s autologous CAR-Treg cell therapies, aimed at treating autoimmune diseases. The agreement covers process transfer, scale-out, and Phase 1/2 clinical manufacturing for multiple candidates in Quell’s pipeline.
AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO), announced a strategic service agreement with CompleCure to support the development of a novel anti-cancer therapeutic. The therapy, based on Antibody Mimetics Drug Conjugate (AMDC) technology, represents a new approach
ten23 health® celebrated the grand opening of its VIVA2® facility in Visp, Switzerland, marking a key development in its contract development and manufacturing organisation (CDMO) services. The new site enhances ten23’s capacity for the sterile filling of vials, syringes, and
Wheeler Bio, a contract development and manufacturing organisation (CDMO), has announced a strategic expansion by licensing ATUM’s miFuc™ platform. The technology enables the production of recombinant proteins, particularly afucosylated antibodies, that offer improved therapeutic windows and increased antibody-dependent cellular cytotoxicity
Nivagen Pharmaceuticals, Inc. has announced the sale of its MedisourceRx business unit to Hims & Hers Health, Inc.. The sale is part of a broader strategic plan by Nivagen to enhance its manufacturing capabilities. MedisourceRx, an FDA-registered 503B outsourcing facility,
Agilent Technologies Inc. has finalised its acquisition of BIOVECTRA, a Canadian contract development and manufacturing organisation (CDMO). The transaction marks the completion of all regulatory approvals, with BIOVECTRA now officially part of Agilent’s Diagnostics and Genomics Group. This acquisition allows
“Our job is to add value, rather than sell stuff and make money.” – David Anchell, Co-Founder and Managing Director of Camida Camida are a specialist supplier of pharmaceutical raw materials, fine chemicals and intermediates to the life sciences industry,
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
